Alk-Abello ASWBO:ALKB -0.12%65 EV-to-FCF is 30.92 as of Jun. 26, 2026, which is 32% below its 10-year median of 45.56. GuruFocus rates WBO:ALKB with a GF Score™ of 65/100 and a GF Value™ of €27.26 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 333 Biotechnology companies, Alk-Abello AS ranks worse than 67.27% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alk-Abello AS's Enterprise Value is €7,436.1 Mil.
Alk-Abello AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €240.5 Mil. Therefore, Alk-Abello AS's EV-to-FCF for today is 30.92.
The historical rank and industry rank for Alk-Abello AS's EV-to-FCF or its related term are showing as below:
WBO:ALKB'
s EV-to-FCF Range Over the Past 10 Years
Min: -1561.81 Med: 45.56 Max: 2297.06
Current: 30.21
During the past 13 years, the highest EV-to-FCF of Alk-Abello AS was 2297.06. The lowest was -1561.81. And the median was 45.56.
WBO:ALKB's EV-to-FCF is ranked worse than 67.27% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs WBO:ALKB: 30.21
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alk-Abello AS's PE Ratio (TTM) for today is calculated as:
Alk-Abello AS's share price for today is €34.22.
Alk-Abello AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.778.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alk-Abello AS EV-to-FCF Related Terms
Alk-Abello AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ALKB vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Alk-Abello AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's EV-to-FCF falls into.
Alk-Abello AS's current Enterprise Value is €7,436.1 Mil.
Alk-Abello AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €240.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (WBO:ALKB) has a EV-to-FCF of 30.92 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alk-Abello AS and its competitors. This is 32% below median its historical median of 45.56. According to the industry distribution chart, Alk-Abello AS ranks #224 out of 333 companies in the Biotechnology industry, placing it in the top 67.3%.
Is Alk-Abello AS's EV-to-FCF too high?
Alk-Abello AS's current EV-to-FCF of 30.92 is 32% below median its 10-year median of 45.56. The Biotechnology industry median EV-to-FCF is 14.65. Alk-Abello AS's value of 30.92 is 111.1% above this industry median. Based on the distribution chart, Alk-Abello AS ranks #224 out of 333 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #224 out of 333 companies for EV-to-FCF. This places Alk-Abello AS in the lower half of its industry. The industry median EV-to-FCF is 14.65. Alk-Abello AS's value of 30.92 is 111.1% above this benchmark. While the company's 10-year median is 45.56 vs. the industry median of 14.65, Alk-Abello AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current EV-to-FCF of 30.92 is 111.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current EV-to-FCF is 30.92, which is 32% below median its own 10-year median of 45.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (WBO:ALKB) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.26, compared to a current price of €34.22 — trading 25.5% above its estimated fair value. The current EV-to-FCF is 30.92, which is 32% below median its 10-year median of 45.56 and 111.1% above the Biotechnology industry median of 14.65. Alk-Abello AS's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Alk-Abello AS (WBO:ALKB), the current EV-to-FCF is 30.92 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of €34.22 is trading 25.5% above its estimated GF Value™ of €27.26.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for WBO:ALKB:
EV-to-FCF: 30.92 (32% below median its 10-year median of 45.56)
GF Value™: €27.26 vs. price of €34.22 (25.5% above fair value)
Industry Position: 111.1% above the Biotechnology median (#224 of 333)
No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
65GF Score
Get the complete analysis for WBO:ALKB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ALKB has been successfully added to your 
